Coherus BioSciences (CHRS) Tops Q4 EPS by 2c
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.29 +4.88%
EPS Growth %: +39.4%
Financial Fact:
Interest expense: -3.14M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: +39.4%
Financial Fact:
Interest expense: -3.14M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q4 EPS of ($0.28), $0.02 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $54.14 million versus the consensus estimate of $44.15 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Downgrades Nucor (NUE) to Hold, 'Guides Conservative Earnings Yet Again'
- Lumentum shares rise on analyst upgrades, AI demand outlook
- On Holding AG (ONON) call put ratio 4.5 calls to 1 put with a focus on September 28 and 29 calls
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
